Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Zosano Pharma	Leap Therapeutics	Aprea Therapeutics	Moleculin Biotech	Cyclerion Therapeutics
Symbol	NASDAQ:ZSAN	NASDAQ:LPTX	NASDAQ:APRE	NASDAQ:MBRX	NASDAQ:CYCN
Price Information
Current Price	$0.74	$1.57	$4.12	$3.30	$2.94
52 Week Range	Buy	Buy	Hold	Buy	N/A
MarketRank™
Overall Score	1.4	1.5	1.6	1.2	1.3
Analysis Score	3.5	3.5	3.1	3.5	0.0
Community Score	2.9	2.6	1.8	2.7	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	2.5	0.0	3.3
Earnings & Valuation Score	0.6	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	N/A
Consensus Price Target	$2.17	$5.38	$14.25	$15.00	N/A
% Upside from Price Target	193.98% upside	242.36% upside	245.87% upside	354.55% upside	N/A
Trade Information
Market Cap	$78.66 million	$93.68 million	$87.29 million	$93.87 million	$100.35 million
Beta	2.98	1.35	0.1	2.11	2.2
Average Volume	8,427,470	759,148	1,275,912	2,314,016	722,214
Sales & Book Value
Annual Revenue	N/A	N/A	N/A	N/A	$4.51 million
Price / Sales	N/A	N/A	N/A	N/A	22.25
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.40 per share	($0.07) per share	$5.92 per share	$0.34 per share	$3.56 per share
Price / Book	N/A	N/A	N/A	N/A	0.83
Profitability
Net Income	$-37,590,000.00	$-32,900,000.00	$-28,060,000.00	$-13,200,000.00	$-123,010,000.00
EPS	($2.29)	($1.47)	($4.67)	($0.32)	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	-2,322.42%
Return on Equity (ROE)	-227.55%	-89.24%	-47.95%	-113.25%	-105.55%
Return on Assets (ROA)	-79.80%	-70.07%	-42.96%	-63.20%	-57.77%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.68%	8.70%	7.49%	4.44%	4.31%
Quick Ratio	0.68%	8.70%	7.49%	4.44%	4.31%
Ownership Information
Institutional Ownership Percentage	10.07%	41.90%	79.31%	4.82%	68.17%
Insider Ownership Percentage	6.10%	25.89%	52.20%	8.30%	10.70%
Miscellaneous
Employees	45	30	11	10	34
Shares Outstanding	106.73 million	59.67 million	21.19 million	28.44 million	34.13 million
Next Earnings Date	8/5/2021 (Estimated)	8/12/2021 (Estimated)	8/10/2021 (Estimated)	8/11/2021 (Estimated)	5/17/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	If You’re Not Bullish on Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Now, You’ll Kick Yourself Later stocksregister.com - May 10 at 3:25 PM
	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Peter M. Hecht Buys 302,000 Shares americanbankingnews.com - May 10 at 11:44 AM
	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares finance.yahoo.com - May 9 at 1:26 PM
	Friday 5/7 Insider Buying Report: CYCN, WY nasdaq.com - May 7 at 1:38 PM
	Stock Alert: Cyclerion Therapeutics Jumps 13% As CEO Raises Stake In Co. nasdaq.com - May 7 at 1:38 PM
	Cyclerion Therapeutics Inc (CYCN) CEO Peter M Hecht Bought $1.7 million of Shares uk.finance.yahoo.com - May 7 at 8:36 AM
	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Purchases $687,000.00 in Stock americanbankingnews.com - May 6 at 11:32 PM
	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Look Bullish in 2021 stocksregister.com - May 1 at 5:36 PM
	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock Forecast 2021: $4 Per Share With Bullish Signs marketingsentinel.com - April 27 at 1:41 PM
	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress finance.yahoo.com - April 27 at 1:41 PM
	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors finance.yahoo.com - April 26 at 8:22 AM
	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) a Suitable Stock for New Investors Now? stocksregister.com - April 24 at 1:06 PM
	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference finance.yahoo.com - April 21 at 9:38 AM
	Cyclerion Therapeutics to Host Pipeline Update Webinar finance.yahoo.com - April 20 at 8:41 AM
	Aavantibio taps Wright as chief medical officer pehub.com - March 30 at 11:51 AM
	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? finance.yahoo.com - March 22 at 8:57 AM
	IXICO selected by Cyclerion for new Alzheimer's disease study prnewswire.com - March 2 at 7:13 AM
	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update finance.yahoo.com - February 25 at 8:14 AM
	CYCN Stock Price Increases Over 25%: Why It Happened pulse2.com - February 4 at 5:28 PM
	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards finance.yahoo.com - January 25 at 8:38 AM
	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? finance.yahoo.com - January 21 at 10:30 AM
	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. apnews.com - January 5 at 10:00 AM
	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference finance.yahoo.com - January 4 at 7:30 AM
	Cyclerion Announces Leadership Transitions finance.yahoo.com - December 21 at 12:23 PM
	Cyclerion Therapeutics, Inc. (CYCN) finance.yahoo.com - December 6 at 9:38 PM

Date	Company	Brokerage	Action
3/22/2021	Zosano Pharma	Maxim Group	Boost Price Target
11/25/2020	Zosano Pharma	HC Wainwright	Lower Price Target
10/22/2020	Zosano Pharma	BTIG Research	Lower Price Target
11/15/2019	Zosano Pharma	Cantor Fitzgerald	Lower Price Target
3/23/2021	Leap Therapeutics	Raymond James	Set Price Target
7/19/2020	Leap Therapeutics	LADENBURG THALM/SH SH	Reiterated Rating
6/29/2020	Leap Therapeutics	Piper Sandler	Initiated Coverage
2/10/2020	Leap Therapeutics	Robert W. Baird	Initiated Coverage
3/23/2021	Aprea Therapeutics	Royal Bank of Canada	Lower Price Target
12/29/2020	Aprea Therapeutics	Morgan Stanley	Lower Price Target
12/16/2020	Aprea Therapeutics	Berenberg Bank	Initiated Coverage
9/29/2020	Aprea Therapeutics	JPMorgan Chase & Co.	Initiated Coverage
6/25/2020	Moleculin Biotech	Oppenheimer	Reiterated Rating
11/18/2019	Moleculin Biotech	Roth Capital	Reiterated Rating
6/3/2019	Cyclerion Therapeutics	Credit Suisse Group	Initiated Coverage

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources